Charles River Laboratories International layoffs, on the record
Every job cut, severance charge and restructuring Charles River Laboratories International reported in its annual reports, 2023 to 2025, quoted from the filings. Headcount went from approximately 21,800 to approximately 19,700.
Headcount, as reported
| Annual report | Employees | As of |
|---|---|---|
| 10-K for 2023 | approximately 21,800 | December 30, 2023 |
| 10-K for 2024 | approximately 20,100 | December 28, 2024 |
| 10-K for 2025 | approximately 19,700 | December 27, 2025 |
Job cuts, severance and restructuring
Our summaryThe company undertook restructuring actions across all reportable segments, including workforce right-sizing that resulted in severance and transition costs and facility consolidation that resulted in asset impairments.
Word for word“Restructuring charges recognized during fiscal year 2023 were approximately $30 million, of which $18 million related to asset impairment and accelerated depreciation charges and $12 million related to severance charges.” 10-K for 2023
Our summaryThe company recorded restructuring costs by segment, with severance and transition costs of $11,608 thousand and asset impairments and other costs of $18,074 thousand in fiscal 2023, for a total of $29,682 thousand.
Word for word“Total restructuring costs $ 11,608 $ 18,074 $ 29,682 Fiscal Year 2022 Severance and Transition Costs Asset Impairments and Other Costs Total (in thousands) Twelve Months Ended Cost of services provided (excluding amortization of intangible assets) $ 928 $ 1,784 $ 2,712 Cost of products sold (excluding amortization of intangible assets) 532 1,765 2,297 Selling, general and administrative 2,441 763 3,204 Total restructuring costs $ 3,901 $ 4,312 $ 8,213 Fiscal Year 2021 Severance and Transition Costs Asset Impairments and Other Costs Total (in thousands) Twelve Months Ended Cost of services provided (excluding amortization of intangible assets) $ 1,898 $ 934 $ 2,832 Cost of products sold (excluding amortization of intangible assets) — — — Selling, general and administrative 2,819 1,205 4,024 Total restructuring costs $ 4,717 $ 2,139 $ 6,856 98 CHARLES RIVER LABORATORIES INTERNATIONAL, INC."” 10-K for 2023
Our summaryThe company expects its completed and planned restructuring actions to yield annualized cost savings.
Word for word“We expect that these effectuated actions as well as other upcoming planned actions will result in approximately $60 million to $70 million of cost savings on an annualized basis.” 10-K for 2023
Our summaryCompany undertook restructuring actions across North America, Europe and Asia, including workforce right-sizing that resulted in severance and transition costs.
Word for word“In response to recent trends observed across each of our businesses, we have undertaken and will continue to implement restructuring actions at various locations across North America, Europe, and Asia.” 10-K for 2024
Our summaryCompany reduced its total headcount through restructuring initiatives that reduce staffing levels to match demand.
Word for word“We have reduced our total headcount by approximately 8% since the end of 2023.” 10-K for 2024
Our summaryCompany stated that its restructuring initiatives are expected to yield annualized cost savings, with about $100 million impacting fiscal 2024.
Word for word“We expect that these effectuated actions, as well as other upcoming planned actions designed to optimize our global footprint to drive greater operating efficiency, will result in approximately $225 million of cost savings on an annualized basis, of which approximately $100 million impacted fiscal 2024.” 10-K for 2024
Our summaryCompany recorded higher severance costs in its DSA segment tied to recent restructuring activities.
Word for word“DSA operating income as a percentage of revenue for fiscal year 2024 was 18.1%, a decrease of 510 bps from 23.2% for fiscal year 2023.” 10-K for 2024
Our summaryCompany recorded higher severance in Manufacturing from recent restructuring activity.
Word for word“Operating income (loss) and operating income (loss) as a percentage of revenue decreased primarily due to the goodwill impairment of $215.0 million within our Biologics Solutions reporting unit, higher severance related to the recent restructuring activity, and accelerated amortization of certain client relationships in the CDMO business due to a change in estimate of the remaining useful life; partially offset by the higher revenue described above and improved operating leverage as well as lower legal costs from an environmental litigation related to the Microbial Solutions business compared to the corresponding period in 2023.” 10-K for 2024
Our summaryCompany recorded higher severance in unallocated corporate costs tied to recent restructuring activities.
Word for word“The increase in unallocated corporate costs of $26.3 million, or 11.4%, compared to fiscal year 2023 is primarily related to severance associated with recent restructuring activities, adjustments to contingent consideration associated with a recent divestiture, and the absence of positive net settlements recognized on virtual power purchase agreements as compared to the corresponding period in 2023.” 10-K for 2024
Our summaryCompany stated it is reducing staffing levels and undertaking restructuring initiatives to align with demand and protect operating margin.
Word for word“Restructuring initiatives to manage costs and generate efficiency by reducing staffing levels to align with the level of demand, as well as evaluating our global footprint to optimize, consolidate, and simplify operations.” 10-K for 2024
Our summaryThe company said it has cut total headcount by about 2% since the end of 2024 as part of restructuring and site consolidation.
Word for word“We have reduced our total headcount by approximately 2% since the end of 2024.” 10-K for 2025
Our summaryThe company reported restructuring charges for fiscal 2025 and 2024, including severance and transition costs from workforce right-sizing.
Word for word“We incurred restructuring charges of $99.8 million and $107.0 million during the fiscal years 2025 and 2024, respectively.” 10-K for 2025
| Fiscal year ended | Severance costs | Restructuring charges | Restructuring costs incurred | Cash paid for restructuring |
|---|---|---|---|---|
| 2016-12-31 | — | $17.9 million | $13.1 million | — |
| 2017-12-30 | — | $4.8 million | $4.3 million | — |
| 2018-12-29 | — | $9.6 million | $8.7 million | — |
| 2019-12-28 | — | $13.8 million | $12.7 million | — |
| 2020-12-26 | — | $12.6 million | $9.3 million | — |
| 2021-12-25 | — | $6.9 million | $5.7 million | $5.6 million |
| 2022-12-31 | $3.9 million | $8.2 million | $6.7 million | $7.3 million |
| 2023-12-30 | $11.6 million | $29.7 million | $11.5 million | $9.6 million |
| 2024-12-28 | $54.2 million | $107 million | — | $43.3 million |
| 2025-12-27 | $29 million | $99.8 million | — | $58.5 million |
Charles River Laboratories International has filed no restructuring notice (Form 8-K, Item 2.05) since 2016. Companies file one only for a cut they judge material, so many announced layoffs never appear as one. This page shows what the company reported to the SEC, not news reports or state layoff notices.
Read from Charles River Laboratories International’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-18. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.